Mereo BioPharma Group (NASDAQ:MREO) Receives "Overweight" Ra

Cantor Fitzgerald reissued their overweight rating on shares of Mereo BioPharma Group (NASDAQ:MREO – Free Report) in a research report released on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $7.00 target price on the stock. Separately, Needham & Company LLC reaffirmed a buy rating and set a $6.00 price objective on shares of […]

Related Keywords

United Kingdom , United States , , Advisors Preferred , News Ratings For Mereo Biopharma Group Daily , Mereo Biopharma Group , Mereo Biopharma Group Price Performance , Sg Americas Securities , Needham Company , Mereo Biopharma Group Company Profile , Cantor Fitzgerald , Index Fund Advisors Inc , Free Report , Biopharma Group , State Equity Partners , Financial Markets , Index Fund Advisors , Get Free Report , Mereo Biopharma Group Daily ,